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Abstract
Results from prevention trials, including the Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT), have fueled
discussion about the cardiovascular (CV) risks associated with non-steroidal anti-inflammatory drugs (NSAIDs). We tested the
hypotheses that (i) adverse CV events reported among ADAPT participants (aged 70 years and older) are associated with
increased ratio of urine 11-dehydrothromboxane B2 (Tx-M) to 293-donor–6-keto-PGF1 (PGI-M) attributable to NSAID
treatments; (ii) coincident use of aspirin (ASA) would attenuate NSAID-induced changes in Tx-M/PGI-M ratio; and (iii) use of
NSAIDs and/or ASA would not alter urine or plasma concentrations of F2-isoprostanes (IsoPs), in vivo biomarkers of free
radical damage. We quantified urine Tx-M and PGI-M, and urine and plasma F2-IsoPs from 315 ADAPT participants using
stable isotope dilution assays with gas chromatography/mass spectrometry, and analyzed these data by randomized drug
assignment and self-report compliance as well as ASA use. Adverse CV events were significantly associated with higher urine
Tx-M/PGI-M ratio, which seemed to derive mainly from lowered PGI-M. Participants taking ASA alone had reduced urine Tx-
M/PGI-M compared to no ASA or NSAID; however, participants taking NSAIDs plus ASA did not have reduced urine Tx-M/
PGI-M ratio compared to NSAIDs alone. Neither NSAID nor ASA use altered plasma or urine F2-IsoPs. These data suggest a
possible mechanism for the increased risk of CV events reported in ADAPT participants assigned to NSAIDs, and suggest
that the changes in the Tx-M/PGI-M ratio was not substantively mitigated by coincident use of ASA in individuals 70 years or
older.
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Introduction
Prostaglandin (PG) H synthase- or cyclooxygenase (COX) 2
inhibitors, also called coxibs, were developed as an alternative for
treatment of arthritis in patients who could not tolerate traditional
(t) non-steroidal anti-inflammatory drugs (NSAIDs). No coxib-
induced increase in risk of adverse cardiovascular (CV) events had
been observed in the relatively short trials of these drugs for
treatment of arthritis (reviewed in [1,2]). Increased rates of adverse
CV events began to emerge instead from longer trials of coxibs for
the prevention or treatment of other diseases [3–5]. In December
2004, increased risk of adverse CV events in groups assigned to
celecoxib in the Adenoma Prevention with Celecoxib study
resulted in the termination of celecoxib administration in this
trial [5]. Upon instruction from the Food and Drug Administra-
tion, coxib treatments were halted days later in five other ongoing
trials with a coxib treatment arm; one of these was the Alzheimer’s
Disease Anti-inflammatory Prevention Trial (ADAPT).
It now appears that exposure to coxibs, perhaps even for even as
little as two weeks [6], provokes a small but significantly increased
risk for adverse CV events that is related in part to the presence of
baseline CV risk factors [1,2]. Although this coxib effect is
probably multifactorial, abundant data from experimental models
suggest that it derives at in part from suppressed production of
prostacyclin (PGI2), especially relative to that of thromboxane (Tx)
A2. Production of TxA2 is closely linked to COX-1 activity while
production of PGI2 is more closely linked to COX-2 activity, with
aspirin preferentially inhibiting COX-1 activity and t-NSAIDs
inhibiting both COX isozymes without bioactivation [7–10].
The degree of CV risk from t-NSAIDs is complicated by several
considerations including variable COX isoform inhibition, inter-
individual variability in response to drug, interaction with other
risk factors for CV disease, and perhaps interaction with aspirin
(ASA) used for cardioprotection [2]. Indeed, others have proposed
that there are different classes of t-NSAIDs with respect to CV
risks, with one class reserved for naproxen because it may provide
cardioprotection in some individuals, but also may compete with
similar effects of ASA [2]. Naproxen was the t-NSAID used along
with celecoxib in ADAPT.
Several of the proposed mechanisms for Alzheimer’s disease
(AD) pathogenesis can be suppressed by t-NSAIDs or by coxibs in
experimental models, and abundant epidemiologic data suggest
that the occurrence of AD is reduced among regular users of t-
NSAIDs [11] (we know of no such data for coxibs). As a result,
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effects of NSAIDs on AD pathogenesis [12]. While none of these
trials demonstrated benefit for patients with the mild (prodromal)
or dementia stages of AD, ADAPT was designed to determine
whether naproxen or celecoxib might prevent subsequent AD
dementia in older individuals with normal cognition at enrollment.
Similar to results in the trials described above, however, a small
but significant increased risk of adverse CV events also was
observed in ADAPT. Somewhat surprisingly, this small risk
appeared more evident in participants assigned to naproxen than
to celecoxib [13].
When considering the increased CV risk observed in ADAPT
participants, it is important to remember that ADAPT differed
from the other NSAID trials in that individuals were older (greater
than 70 years), and enriched for risk of AD but not for
rheumatologic, neoplastic, or CV diseases. Both attributes of
ADAPT participants might have influenced baseline CV risk and
thereby the risk for adverse CV events from NSAID use.
Moreover, unlike some of the previous trials, ADAPT permitted
use of cardioprotective ASA, which about half of the relatively
more elderly ADAPT cohort used. Here we describe investigation
of biomarkers for proposed mechanisms of NSAID-induced
adverse CV events in ADAPT participants.
Methods
ADAPT was a multisite randomized, placebo-controlled,
parallel chemoprevention trial conducted in individuals who were
70 years or older and had a family history of AD [13]. Study
treatments in ADAPT were celecoxib at a full anti-arthritic dose of
200 mg taken twice daily, and naproxen sodium at the dosage
authorized for over-the-counter use: 220 mg taken twice daily.
ADAPT participants were permitted voluntary concomitant use of
cardioprotective ASA not to exceed 1000 mg/week. We estimated
systemic biosynthesis of thromboxane (Tx) A2, which derives
predominantly from the catalytic action of COX-1, and
prostacyclin (PGI2), which derives predominantly from the
catalytic action of COX-2, by quantifying their respective major
urinary metabolites, 11-dehydrothromboxane B2 (Tx-M) and 293-
donor–6-keto-PGF1 (PGI-M) [7–9]. We also quantified urine and
plasma F2-isoprostanes (IsoPs) since these in vivo biomarkers of
oxidative injury have been proposed by some to derive in part
from the action of COX isozymes [14,15].
Enrollment commenced in March 2001 and administration of
ADAPT treatments was suspended on 17 December 2004. We
analyzed specimens from all 330 ADAPT participants who had
donated fluids before the suspension date. This number included
38 donors who had experienced adverse CV events (see below).
We dichotomized the 330 participants according to the self-
reported regularity with which they took their assigned treatments.
‘‘Compliant’’ individuals reported that they took their treatments
‘‘always or almost always’’, ‘‘most of the time’’, or ‘‘about half of
the time.’’ ‘‘Non-compliant individuals’’ reported adherence to
their assigned treatment regimen ‘‘less than half the time’’,
‘‘infrequently’’, or ‘‘never’’. Fourteen individuals did not provide
data on their treatment compliance, and one sample from the
‘‘compliant’’ group was lost. Therefore, we determined the
concentrations of the three biomarkers in samples from the
remaining 315 participants.
Tx-M, PGI-M, and F2-IsoPs were quantified using stable
isotope dilution assays with gas chromatography/mass spectrom-
etry, as previously described [9,16]. Results below the limit of
detection for any analyte were assigned a value of zero for that
analyte. Occasional spectra were not resolvable and were treated
as missing. This resulted in 23 missing Tx-M samples and 20
missing PGI-M samples. Urine concentrations were expressed in
ng/mg of creatinine. Statistical analyses were performed initially
using GraphPad Prism version 4.03 (GraphPad Software, San
Diego, CA) with a=0.05, and confirmed in Stata, version 10
(STATA Corporation, College Station, TX).
Results
Participant Characteristics
The compliant (n=190) and non-compliant (n=125) groups
did not differ with respect to age (mean 6 SD: 7664 vs. 7764
years; P.0.05), gender (89 women and 101 men in the compliant
group, vs. 70 and 55 in non-compliant participants; x
2 test;
P.0.05), education (mean 6 SD: 1563 years for both), or
presence of the APOE e4 allele (18% vs. 22%; P.0.05).
Associations of NSAID and ASA Use with COX-Derived
Metabolites
Data were considered in separate two-way ANOVAs for urinary
Tx-M or PGI-M concentrations in compliant and non-compliant
participants, some of whom also voluntarily took ASA (Table 1).
Average age 6 SD and % female for ASA users were 7764 years
and 55% female, and for ASA non-users were 7664 and 56%
female. Treatment group assignment was a statistically significant
predictor of urine Tx-M and PGI-M concentrations in the
compliant group (P,0.0001 for each group). Urine Tx-M and, to
a lesser degree, urine PGI-M concentrations also were reduced
significantly with ASA use in the compliant group (P,0.0001 and
P,0.05). Among compliant subjects, there was a significant
statistical interaction between treatment assignment and ASA use
for urinary concentration of Tx-M, but not of PGI-M. This
interaction reflected a significant additional suppressive effect of
ASA use on Tx-M levels in subjects compliant to placebo or
celecoxib (P for either,0.0001), but not naproxen. As expected,
the non-compliant group showed no significant effect of treatment
assignment on either urine Tx-M or PGI-M concentrations
(P.0.05 for both). However, non-compliant participants who
were ASA users did show significantly reduced concentrations of
Tx-M but not PGI-M (P,0.05). There was no evidence of a
statistical interaction between group assignment and ASA use
among non-compliant participants. In summary, we observed the
expected changes in urine Tx-M and PGI-M concentrations by
treatment assignment and by ASA use among compliant ADAPT
participants, and by ASA use among non-compliant donors.
Relation of Prostaglandin Metabolites to Serious
Cardiovascular Adverse Events
We contrasted urine Tx-M, urine PGI-M, and the ratio of these
two analytes in the 38 individuals with a composite cardiovascular
endpoint including cardiovascular death, myocardial infarction, or
stroke (CV+) vs. the other 277 participants without such events
(CV2). Average age 6 SD and % female for the CV+ group were
7763 years and 42% female, and for the CV2 group were 7664
years and 51% female. Non-parametric Mann-Whitney t-tests
showed that urinary PGI-M was significantly lower in the CV+
group (0.1060.01 ng/mg Cr) than in the CV2 group
(0.1560.01 ng/mg Cr; P=0.01). Urine Tx-M levels also tended
to be higher in CV+ individuals, but these values did not differ
significantly from those of CV2 subjects. As predicted, the ratio of
urine Tx-M/PGI-M was significantly higher in the CV+ group
(3.4560.43 ng/mg Cr) vs. CV2 group (3.0860.29 ng/mg Cr;
P,0.05). Although the number of adverse events in the cohort was
relatively small, these data suggest that higher urine Tx-M/PGI-M
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participants.
We sought also to determine whether co-incident use of ASA
would ameliorate NSAID-induced shifts in the urine Tx-M/PGI-
M ratio (Figure 1). Here we restricted our analysis to compliant
participants. Treatment group assignment (P=0.001), but not
ASA use (P.0.05) significantly affected urine Tx-M/PGI-M ratio.
Bonferroni-corrected post-hoc paired comparisons showed that
placebo had significantly lower ratios than naproxen- or celecoxib-
assigned groups who were also voluntary ASA users (P,0.05 and
,0.001, respectively). Although a similar trend was observed
among participants who did not use ASA, these differences were
not statistically significant. When comparing the effects of ASA use
within treatment groups, only placebo-assigned ASA users had a
significantly (P,0.05) lower ratio than did participants who did
not report use of ASA. Although not originally specified as part of
the trial design and relying on self-reported ASA use, these results
suggest that co-incident use of ASA did not offset celecoxib-
induced changes in urine Tx-M/PGI-M ratio in ADPAT
participants.
F2-IsoPs Concentrations
The concentrations of urine and plasma F2-IsoP were
significantly correlated (P,0.01), but neither showed a significant
relationship to treatment assignment or ASA use in compliant or
non-compliant participants. Among compliant participants, plas-
ma F2-IsoP concentrations were 5269 pg/ml (average 6 SEM)
for the 27 placebo-assigned subjects who did not use ASA vs.
6065 pg/ml for the 47 who did use ASA. In the urine, F2-IsoP
concentrations were 2.260.3 ng/mg Cr for 29 compliant placebo-
assigned subjects who did not use ASA vs. 2.060.1 ng/mg Cr for
the 52 who did use ASA. There was no evidence for an interaction
between treatment group assignment and ASA use for F2-IsoPs in
either plasma or urine. In summary, neither NSAIDs nor ASA had
a significant effect on plasma or urine concentrations of this
quantitative in vivo measure of free radical damage in ADAPT
participants.
Table 1. Urine Tx-M and PGI-M concentrations in ADAT participants categorized by treatment adherence, group assignment, and
aspirin use.
Urine eicosanoid Adherence Assignment No Aspirin (n) Aspirin (n)
Tx-M (ng/mg Cr) Compliant
+ Placebo 0.45+0.04 (27) 0.22+0.02 (52)
#, *
Naproxen 0.23+0.05 (29) 0.17+0.02 (27)
#
Celecoxib 0.40+0.04 (16) 0.16+0.02 (26)
#, *
Subtotal 0.35+0.03 (72) 0.19+0.01 (105)
++
Non-compliant
‘ Placebo 0.43+0.07 (20) 0.29+0.09 (21)
#
Naproxen 0.36+0.07 (13) 0.20+0.03 (26)
#
Celecoxib 0.35+0.06 (10) 0.21+0.03 (25)
#
Subtotal 0.39+0.04 0.23+0.03
++
PGI-M (ng/mg Cr) Compliant
+ Placebo 0.23+0.02 (29) 0.16+0.02 (50)
#
Naproxen 0.11+0.02 (26) 0.10+0.03 (27)
#
Celecoxib 0.12+0.02 (18) 0.06+0.01 (29)
#
Subtotal 0.16+0.01 (73) 0.12+0.01 (106)**
Non-compliant
‘ Placebo 0.18+0.03 (19) 0.15+0.04 (21)
Naproxen 0.15+.02 (14) 0.13+0.02 (26)
Celecoxib 0.13+0.02 (9) 0.12+0.02 (27)
Subtotal 0.16+0.01 (42) 0.13+0.01 (74)**
Two-way ANOVAs were performed for each eicosanoid in compliant and non-compliant subjects for the three treatment groups. Group assignment was significantly
(
+P,0.0001) related to urine Tx-M and PGI-M in the compliant group, but not for the non-compliant group (
‘P.0.05). ASA use was associated with reduced urine Tx-M
concentrations (
#P,0.05) in the compliant and non-compliant groups, and reduced urine PGI-M in only the compliant group (
#P,0.05). A significant interaction
between group assignment and ASA use (P,0.05) was detected only for urine Tx-M concentrations in the compliant group. Bonferroni-corrected post-hoc comparisons
evaluated the effects of ASA use in each of the twelve groups; only urine Tx-M in compliant Placebo and compliant celecoxib participants was significant (*P,0.0001)
while all others had P.0.05. In addition, values for ASA compliant and noncompliant individuals were calculated regardless of treatment group assignment, presented
in rows labeled subtotal, and compared using t-tests (
++P,0.0001, **P,0.05).
doi:10.1371/journal.pone.0009340.t001
Figure 1. Urine Tx-M/PGI-M ratio in compliant ADAPT partic-
ipants who self-reported ASA use was analyzed by two-way
ANOVA; treatment group assignment (P,0.01), but not ASA
use significantly affected this ratio. Bonferroni-corrected post-hoc
t-tests showed that among treatment groups, only Placebo was
significantly different (P,0.05) between ASA and No ASA users.
doi:10.1371/journal.pone.0009340.g001
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We undertook analyses of urine and plasma samples from
ADAPT participants to determine whether naproxen or celecoxib
treatment in individuals 70 years or older produced changes in
urine Tx-M and PGI-M levels that were similar to findings
reported previously in younger individuals. We also sought to test
three hypotheses: (i) that CV adverse events in ADAPT
participants were associated with an increase in the Tx-M/PGI-
M ratio, (ii) that use of ASA might ameliorate NSAID-induced
changes in urine Tx-M/PGI-M ratio, and (iii) that use of NSAIDs
and/or ASA would alter urine or plasma F2-IsoP concentrations.
Production of TxA2 is closely linked to COX-1 activity while
production of PGI2 is more closely linked to COX-2 activity [7–
10]. Our results showed relative suppression of the major urinary
metabolites, Tx-M or PGI-M, that varied with selective inhibition
of COX isoforms by these drugs. In addition, serious adverse CV
events in ADAPT participants were significantly associated with a
higher urine Tx-M/PGI-M ratio, which in turn seemed to derive
mainly from lowered PGI-M. These were the expected results
based on previous studies and exclude the possibility of unexpected
pharmacologic activity in this older cohort. However, increased
CV risk in ADAPT was observed more in the t-NSAID (naproxen)
than in the coxib group. While it is true that both of these ADAPT
treatment groups had higher urine Tx-M/PGI-M ratio compared
to placebo, the highest values were observed with coxib users. As is
now clear from several studies, adverse CV events from NSAID
use are multifactorial and dependent in part on baseline CV risk
factors that may not have been adequately balanced by the
randomization process in ADAPT. Unfortunately, because CV
events were not originally intended as an outcome measure in
ADAPT, we do not have good data on CV risks in participants at
baseline. It is therefore possible that some combination of drug-
induced changes and a lack of balance in baseline CV risk factors
accounts for small increased CV risks that appeared among
naproxen users in ADAPT.
It has been suggested that co-incident treatment with ASA
might protect against unfavorable NSAID-induced shifts in the
production of TxA2 and PGI2. ADAPT was not designed to test
effects of ASA (use was not randomized), so our data are only
suggestive. They do, however, indicate that participants taking
NSAIDs and ASA did not have a reduced urine Tx-M/PGI-M
ratio. To the extent that the cardioprotection from ASA use is
reflected in the Tx-M/PGI-M ratio, therefore, our data suggest
that the cardioprotective effects of ASA are modest in individuals
using NSAIDs according to the ADAPT protocol.
F2-IsoPs are widely used, validated quantitative in vivo measures
of free radical damage [17]. Some have proposed that F2-IsoPs
also can derive from COX activity, thereby complicating the
interpretation of changes in concentrations of these biomarkers
[14,15]. However, unlike the two COX-derived metabolites
discussed above, plasma and urine F2-IsoP concentrations were
not significantly changed with use of celecoxib, naproxen, or ASA
in ADAPT participants. We conclude that, similar to findings in
animal models [17], COX-induced production of F2-IsoPs occurs
at undetectable levels in older humans.
Our results showed that, similar to results reported from
younger cohorts, ADAPT participants who were compliant with
their assigned treatment regimen showed expected changes in
urine Tx-M and PGI-M, but not in plasma or urine F2-IsoPs.
Moreover, as expected, adverse CV events were associated with an
increased Tx-M/PGI-M ratio. Importantly, however, our results
also suggested that these effects were not materially modified with
self-reported voluntary use of ASA. Our data thus provide a partial
mechanistic explanation for the increase risk for CV events
reported in ADAPT, but they also suggest that this risk from
NSAID use might not be substantively mitigated by co-
administration of ASA, at least in those over 70 years of age.
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